United States - English - NLM (National Library of Medicine)

mission pharmacal company - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - zinc oxide 10 g in 100 g - uses temporarily protest minor: - cuts - scrapes - burns temporarily protects and helps relieve chapped, chafed, or cracked skin. helps protect from the dying effects of wind and cold weather. helps treat and prevent rash caused by adult incontinence. do not use on - deep or puncture wounds - animal bites - serious burns directions apply as needed to affected area. to report a serious adverse event or obtain product information, call (210) 696-8400 mission pharmacal company san antonio, tx 78230-1355 51023 rev 011120

United States - English - NLM (National Library of Medicine)

mission pharmacal company - potassium iodide (unii: 1c4qk22f9j) (iodide ion - unii:09g4i6v86q) - potassium iodide 65 mg in 1 ml - purpose thyroid blocking uses helps prevent radioactive iodine from getting into the thyroid gland during a nuclear radiation emergency. use along with other emergency measures recommended by public officials. potassium iodide oral solution is a thyroid blocking medicine that is used in a nuclear radiation emergency only.

United States - English - NLM (National Library of Medicine)

mission pharmacal company - tiopronin (unii: c5w04go61s) (tiopronin - unii:c5w04go61s) - tiopronin 100 mg - thiola ® is indicated for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification, or who have adverse reactions to d-penicillamine. cystine stones typically occur in approximately 10,000 persons in the united states who are homozygous for cystinuria. these persons excrete abnormal amounts of cystine in urine of over 250 mg/g creatinine, as well as excessive amounts of other dibasic amino acids (lysine, arginine and ornithine). in addition, they show varying intestinal transport defects for these same amino acids. the stone formation is the result of poor aqueous solubility of cystine. since there are no known inhibitors of the crystallization of cystine, the stone formation is determined primarily by the urinary supersaturation of cystine. thus, cystine stones could theoretically form whenever urinary cystine concentration exceeds the solubility limit. cystine solubility in urine is ph-dependent, and ranges from 170-300 mg/liter at ph 5, 190-400 mg/liter at ph 7 and 220-500 mg/liter at ph 7.5. the goal of therapy is to reduce urinary cystine concentration below its solubility limit. it may be accomplished by dietary means aimed at reducing cystine synthesis and by a high fluid intake in order to increase urine volume and thereby lower cystine concentration. unfortunately, the above conservative measures alone may be ineffective in controlling cystine stone formation in some homozygous patients with severe cystinuria (urinary cystine exceeding 500 mg/day). in such patients, d-penicillamine has been used as an additional therapy. like thiola ™ , dpenicillamine undergoes thiol-disulfide exchange with cystine, thereby lowering the amount of sparingly soluble cystine in urine. however, d-penicillamine treatment is frequently accompanied by adverse reactions, such as dermatologic complications, hypersensitivity reactions, hematologic abnormalities and renal disturbances. thiola ® may have a particular therapeutic role in such patients. the use of thiola ® during pregnancy is contraindicated, except in those with severe cystinuria where the anticipated benefit of inhibited stone formation clearly outweighs possible hazards of treatment (see precautions). thiola ® should not be begun again in patients with a prior history of developing agranulocytosis, aplastic anemia or thrombocytopenia on this medication. mothers maintained on thiola ® treatment should not nurse their infants.

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - meclizine hydrochloride (unii: hdp7w44cio) (meclizine - unii:3l5tq84570) - meclizine hydrochloride 25 mg - indications based on a review of this drug by the national academy of sciences – national research council and/or other information, fda has classified the indications as follows: effective: management of nausea and vomiting, and dizziness associated with motion sickness. possibly effective: management of vertigo associated with diseases affecting the vestibular system. final classification of the less than effective indications required further investigation. meclizine hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. thiazides are indicated in pregnancy when edema is du

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - indomethacin (unii: xxe1cet956) (indomethacin - unii:xxe1cet956) - carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). indomethacin has been found effective in active stages of the following: - moderate to severe rheumatoid arthritis including acute flares of chronic disease. - moderate to severe ankylosing spondylitis. - moderate to severe osteoarthritis. - acute painful shoulder (bursitis and/or tendinitis). - acute gouty arthritis. indomethacin is contraindicated in patients with known hypersensitivity to indomethacin or the excipients (see description). indomethacin should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/anaphylactoid reactions to nsaids have been reported in such patients (see warnings: anaphylactic/anaphylactoid reactions, and pr

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - indomethacin (unii: xxe1cet956) (indomethacin - unii:xxe1cet956) - carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). indomethacin has been found effective in active stages of the following: - moderate to severe rheumatoid arthritis including acute flares of chronic disease. - moderate to severe ankylosing spondylitis. - moderate to severe osteoarthritis. - acute painful shoulder (bursitis and/or tendinitis). - acute gouty arthritis. indomethacin is contraindicated in patients with known hypersensitivity to indomethacin or the excipients (see description). indomethacin should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/anaphylactoid reactions to nsaids have been reported in such patients (see warnings: anaphylactic/anaphylactoid reactions, and pr

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. most patients heal within 4 weeks. some patients may require an additional 4 weeks of therapy. omeprazole delayed-release capsules, in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease (active or up to one year history) to eradicate h. pylori in adults. omeprazole delayed-release capsules, in combination with clarithromycin are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease to eradicate h. pylori in adults. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies (14.1) and dosage and administration (2)]. among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. in pati

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg - cephalexin capsules are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by streptococcus pneumoniae and streptococcus pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to streptococcus pneumoniae, haemophilus influenzae, staphylococcus aureus, streptococcus pyogenes, and moraxella catarrhalis skin and skin structure infections caused by staphylococcus aureus and/or streptococcus pyogenes bone infections caused by staphylococcus aureus and/or proteus mirabilis genitourinary tract infections, including acute prostatitis, caused by escherichia c

United States - English - NLM (National Library of Medicine)

hi-tech pharmacal co. inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297) - neomycin sulfate 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of neomycin sulfate tablets and other antibacterial drugs, neomycin sulfate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidimiology and susceptibility patterns may contribute to the empiric selection of therapy. suppression of intestinal bacteria : neomycin sulfate tablets are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel, eg, preoperative preparation of the bowel. it is given concomitantly with erythromycin enteric-coated base (see dosage and administration section) . hepatic coma (portal-systemic encephalopathy) : neomycin sulfate has been shown to be effective adjunctive therapy in hepatic com